185 related articles for article (PubMed ID: 35601756)
1. Efficacy of prolonged-release fampridine
Hupperts R; Gasperini C; Lycke J; Ziemssen T; Feys P; Xiao S; Acosta C; Koster T; Hobart J
Ther Adv Neurol Disord; 2022; 15():17562864221090398. PubMed ID: 35601756
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
5. Erratum.
Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
[TBL] [Abstract][Full Text] [Related]
6. Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.
Kim ES
Drugs; 2017 Sep; 77(14):1593-1602. PubMed ID: 28864863
[TBL] [Abstract][Full Text] [Related]
7. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
[TBL] [Abstract][Full Text] [Related]
8. Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
Prugger M; Berger T
Patient Relat Outcome Meas; 2013; 4():75-85. PubMed ID: 24187513
[TBL] [Abstract][Full Text] [Related]
9. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
[TBL] [Abstract][Full Text] [Related]
11. Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial.
Dadvar A; Jameie M; Azizmohammad Looha M; Parsaei M; Zeynali Bujani M; Amanollahi M; Babaei M; Khosravi A; Amirifard H
PLoS One; 2024; 19(2):e0297235. PubMed ID: 38349929
[TBL] [Abstract][Full Text] [Related]
12. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
15. Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.
Castelnovo G; Gerlach O; Freedman MS; Bergmann A; Sinay V; Castillo-Triviño T; Kong G; Koster T; Williams H; Gafson AR; Killestein J
CNS Drugs; 2021 Sep; 35(9):1009-1022. PubMed ID: 34322853
[TBL] [Abstract][Full Text] [Related]
16. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
[TBL] [Abstract][Full Text] [Related]
17. Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.
Sola-Valls N; Blanco Y; Sepúlveda M; Llufriu S; Martínez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Montejo C; Villoslada P; Saiz A
Ther Adv Neurol Disord; 2018; 11():1756286418780007. PubMed ID: 29977342
[TBL] [Abstract][Full Text] [Related]
18. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
[TBL] [Abstract][Full Text] [Related]
19. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
20. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
